Skip to content
Taxonomy
Progress Update: Timmerman’s CMT1A Organoid Project Shows Early Success CMTA is excited to report significant progress in its strategic Read More
Breakthrough in CMT1A Research: Community Efforts Drive Success of Dental Stem Cell Model With the incredible support of the CMT community, Esther Wolfs, Read More
CMTA Partners with Actio Bio on CMT2C Focus Group The Charcot-Marie-Tooth Association (CMTA), in collaboration with Actio Biosciences (Actio Read More
CMT2F Natural History Study Nears Full Recruitment as Biomarker Analysis Begins With CMTA support of $302,071, an international team of researchers Read More
CMTA’s CRISPR Research Initiative Advances for CMT1A and CMT1B The Charcot-Marie-Tooth Association (CMTA) continues its mission to accelerate research Read More
Your Participation Matters: Join the CMT2S Research Study CMT2S: A Potential New Treatment on the Horizon Charcot-Marie-Tooth Disease Read More
CMTA’s Strategic Investment Advances Research for CMT1A and CMT1B The Charcot-Marie-Tooth Association (CMTA) continues its mission to accelerate research Read More
Exploring New Therapeutic Pathways for CMT1B: UPR Activation Researchers at the Ospedale San Raffaele (OSR) Scientific Institute in Read More
Advancing the Understanding of CMT2A and CMT2F: A Call to Beat CMT The Charcot-Marie-Tooth Association (CMTA), through its Strategy To Accelerate Research Read More
CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news Read More
